Read the Latest News

Join Us AT TMJ Cafe

The TMJ Association is pleased to partner with Inspire to bring you the TMJ Cafe, a free online support network and discussion community for those with Temporomandibular Disorders (TMD). We invite you to meet others like you, share experiences and tips for getting through the day, and give and receive support.

Sustained and Repeated Mouth Opening Leads to Development of Painful Temporomandibular Disorders Involving Macrophage/Microglia Activation in Mice

Temporomandibular disorder (TMD) is a set of heterogeneous musculoskeletal conditions involving the temporomandibular joint (TMJ) and/or the masticatory muscles. Up to 33% of the population has had at least one symptom of TMD with 5-10% of them requiring treatment. Common symptoms include limited jaw movement, joint sound, and pain in the orofacial area. Once TMD becomes chronic, it can be debilitating with comorbidities that greatly reduce one's overall quality of life. However, the underlying mechanism of TMD is unclear due to the multicausative nature of the disease.

Prevalence of TMD in Sjӧgren Syndrome Patients

Sjӧgren's Syndrome seems to play a role in temporomandibular joint disorders.

Early Molecular Response and Microanatomical Changes in the Masseter Muscle and Mandibular Head After Botulinum Toxin Intervention in Adult Mice

The Botox-injected masseters had greatly increased expression of genes involved in muscle atrophy at the 1 week time point compared to the control side muscles. At the end of the study, 2 weeks after injection, the Botox-injected masseters were about 20% smaller than the control side masseters, and the Botox-side condyles had lost about 40% of relative bone area compared to the control side condyles.

Centralized Pain in TMD: Is It All in the Head?

We are pleased to introduce Sophia Stone, a new contributor to The TMJ Association, whose passion is to separate TMD fact from TMD fiction. Sophia has a background in medicine and research and can draw on her personal experience as a TMD patient.

NIH GRANT OPPORTUNITIES

  • Mar 29, 2018

In an effort to promote greater understanding of Temporomandibular Disorders (TMD) and to develop safe and effective evidence-based diagnostics and treatments. The TMJ Association promotes and encourages basic and clinical research on TMD.  We invite you to view a listing of the latest National Institutes of Health (NIH) funding opportunities for scientists interested in advancing TMJ research.

 

Clinical Validation of Candidate Biomarkers for Neurological Diseases

  • Posted Date: February 14, 2018
  • Open Date: March 17, 2018
  • Expires: April 17, 2018; July 18, 2018; February, 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020
The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond).
 

Research on the Health of Women of Understudied, Underrepresented and Underreported

(U3) Populations An ORWH FY18 Administrative Supplement (Admin Supp - Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/PA-18-676.html
  • Posted Date: February 22, 2018
  • Open Date: March 16, 2018
  • Expires: April 17, 2018  

The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support interdisciplinary, transdisciplinary and multidisciplinary research focused on the effect of sex/gender influences at the intersection of a number of social determinants, including but not limited to: race/ethnicity, socioeconomic status, education, health literacy and other social determinants in human health and illness. This research includes preclinical, clinical and behavioral studies with the specific purpose to provide Administrative Supplements to active NIH parent grants for one year to address health disparities among women of populations in the US who are understudied, underrepresented and underreported in biomedical research.

The proposed research must address an area specified within Objective 3.9 (Goal 3.0) of the NIH Strategic Plan for Research on Women's Health (http://orwh.od.nih.gov/research/strategicplan/index.asp) which states: "Examine health disparities among women stemming from differences in such factors as race and ethnicity, socioeconomic status, gender identity, and urban-rural living, as they influence health, health behaviors, and access to screening and therapeutic interventions."

Specialized Centers of Research Excellence (SCORE) on Sex Differences

 

Factors Underlying Differences in Female and Male Presentation for Dental, Oral, and Craniofacial Diseases and Conditions

(R01): http://grants.nih.gov/grants/guide/pa-files/PA-16-295.html

(R21): http://grants.nih.gov/grants/guide/pa-files/PA-16-296.html

  • Posted Date: May 27, 2016
  • Open Date: September 16, 2016
  • Expires: September 8, 2019

The purpose of this funding opportunity announcement (FOA) is to encourage research on mechanisms underlying the manifestations of sex-based differences in Dental, Oral, and Craniofacial (DOC)-related diseases and conditions.  Specifically, this initiative encourages studies aimed at understanding immune reactivity, genetic variation, environmental triggers, aging, and hormonal changes as they affect sex-based differences in DOC-related diseases and conditions including, but not limited to, Sjögren’s Syndrome (SS), orofacial pain, temporomandibular joint (TMJ) disorder (TMD), salivary gland tumors, and human papillomavirus (HPV)-associated oropharyngeal cancers. 

 

NIDCR Small Research Grants for Secondary Analysis of FaceBase Data (R03)

(R03): http://grants.nih.gov/grants/guide/pa-files/PAR-16-362.html

  • Posted Date: July 11, 2016
  • Open Date: September 16, 2016
  • Expires: September 8, 2019

The FaceBase Consortium is developing a variety of comprehensive datasets on craniofacial development that are available to the wider scientific community at www.facebase.org. This funding opportunity announcement (FOA) will support meritorious research projects that conduct secondary data analyses of these FaceBase datasets relevant to craniofacial development, human craniofacial conditions or traits, and animal models of those craniofacial conditions.  Informatics projects that integrate data from multiple FaceBase datasets are especially encouraged. 

 

Tailoring Dental Treatment for Individuals with Systemic Diseases that Compromise Oral Health

(R01): http://grants.nih.gov/grants/guide/pa-files/PAR-16-154.html

(R21): http://grants.nih.gov/grants/guide/pa-files/PAR-16-153.html

  • Posted Date: March 25, 2016
  • Open Date: May 16, 2016
  • Expires: May 8, 2019

This Funding Opportunity Announcement encourages research to address gaps in our knowledge of how best to treat oral diseases of patients with systemic diseases or conditions known to compromise oral health, to identify factors predictive of treatment outcomes within patient groups, and to generate evidence for more precise dental treatment guidelines tailored to patient needs. It is expected that research applications will propose studies utilizing established cohorts of individuals with the disease of interest.

 

Personalized Strategies to Manage Symptoms of Chronic Illness

(R15): http://grants.nih.gov/grants/guide/pa-files/PA-16-006.html

(R01): http://grants.nih.gov/grants/guide/pa-files/PA-16-007.html

(R21): http://grants.nih.gov/grants/guide/pa-files/PA-16-008.html

  • Posted Date: October 16, 2015
  • Open Date: January 25, 2016
  • Expires: January 8, 2019

The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. 

 

Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing

(R01): http://grants.nih.gov/grants/guide/pa-files/PA-15-347.html

  • Posted Date: September 17, 2015
  • Open Date: January 5, 2016
  • Expires: January 8, 2019

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that elucidate the mechanisms and/or behavioral outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and cognate perceptual quality.  Specifically, multiple sensory inputs may include the major traditional modalities of hearing, vision, taste, smell, balance, and touch.  Additional submodalities of body senses include but are not restricted to thermosensation, body position and proprioception, pain, itch, and general visceral sensation.  This FOA encourages research grant applications investigating multisensory processing in perception or other behavioral and social outcomes and/or the mechanisms underlying multisensory processing in the context of the described specific areas of research interests from the participating NIH Institutes, Centers, and Offices (ICOs).  The FOA is intended to encourage basic, behavioral, and/or clinical research projects examining the interactions between other neural systems, such as cognitive, affective, or motor processes, and multiple sensory modalities.  Multisensory research applications that do not align with the specific areas of research interests described below by the participating NIH ICOs should be submitted to the parent R01 FOA, PA-13-302.

 

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System

(UH2/UH3): https://grants.nih.gov/grants/guide/pa-files/PAR-17-205.html

  • Posted Date: March 9, 2017
  • Open Date: July 9, 2017
  • Expires: May 8, 2020

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

NIDCR is interested in neurotherapeutics development for painful disorders of the orofacial region including temporomandibular joint disorder, trigeminal neuropathies, burning mouth syndrome, and other conditions.  Recent advances in genomics and phenotyping of subjects with orofacial pain conditions have expanded the scope of potential targets to treat these conditions. Receptor systems, ion channels, and pro- and anti-inflammatory molecules have been implicated in chronic pain. NIDCR is interested in supporting research that will lead to highly efficacious and specific pharmacological treatments of subjects with orofacial pain disorders.

Investigators are encouraged to contact NIDCR program staff to discuss potential research projects prior to application submission to determine alignment of the planned studies with priorities of the Institute mission and strategic plan.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.     - See more at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html#sthash.mGoDkIgW.dpuf
The purpose of this Funding Opportunity Announcement (FOA)is to encourage research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which we do not have a strong understanding of the genetics/genomics of the disease or disorder. Applicable areas of investigation include identification of promising areas of the genome, and characterization and elucidation of the function(s) of genetic variants that affect disease risk in humans. The ultimate goal of these studies will be to drive development of effective diagnostic, therapeutic, and preventive approaches. - See more at: http://grants.nih.gov/grants/guide/pa-files/PA-14-347.html#sthash.viviyVB9.dpuf

 

Population Health Interventions: Integrating Individual and Group Level Evidence

(R01): https://grants.nih.gov/grants/guide/pa-files/PA-18-356.html

  • Posted Date: November 21, 2017
  • Open Date: January 5, 2018
  • Expires: May 8, 2019

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

 

Family-Centered Self-Management of Chronic Conditions

(R21): https://grants.nih.gov/grants/guide/pa-files/PA-18-380.html

(R01):https://grants.nih.gov/grants/guide/pa-files/PA-18-383.html

  • Posted Date: November 21, 2017
  • Open Date: January 16, 2018 / January 5, 2018
  • Expires: January 8, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of family-centered self-management (FCSM) in chronic conditions.

 

mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management

(R01): https://grants.nih.gov/grants/guide/pa-files/PA-18-386.html

(R21): https://grants.nih.gov/grants/guide/pa-files/PA-18-389.html

  • Posted Date: November 21, 2017
  • Open Date: January 5, 2018
  • Expires: January 8, 2021

The purpose of this initiative is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. 

The Biomarkers Consortium

The Biomarkers Consortium, a research partnership managed by the Foundation for the National Institutes of Health, is soliciting concepts for biomarker projects. Researchers are encouraged to submit project concepts online at http://www.biomarkersconsortium.org. If a concept is approved for development by the consortium, the Foundation for NIH will seek funds to support the project.

The consortium is a large-scale, public-private research partnership formed in 2006 to identify and qualify biomarkers. It encourages participation by academia, government, industry, patient advocacy groups and other non-profit organizations. In addition to the Foundation for NIH, founding members of the consortium include the NIH, the Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America.

Information about the Foundation for NIH is available at http://www.fnih.org.

 

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

  • Posted Date: December 21, 2017
  • Open Date: January 7, 2018
  • Expires: May 8, 2020

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. 

 

This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf
This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf
This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf

In Treating TMJ

To view or order a free booklet about TMJ Disorders, visit the National Institutes of Health website.

U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
National Institutes of Health
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health